Alcon Reports Q3 2025 Sales of $2.6 Billion, Up 6% YoY, and Maintains Full-Year Guidance

Alcon reported Q3 2025 sales of $2.6 billion, up 6% YoY, with constant currency sales up 5%. The company generated $1.6 billion in cash from operations and $1.2 billion in free cash flow in the first nine months of 2025. Alcon returned $550 million to shareholders and maintained its full-year 2025 guidance. The company saw strong acceleration in equipment sales and growth in ocular health. Unity VCS momentum is building, and PanOptix Pro and Tryptyr are gaining traction in the market.